Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Infectious Disease › Skin colonization by Candida auris is a key factor in high transmissibility and outbreak potential

Skin colonization by Candida auris is a key factor in high transmissibility and outbreak potentialSkin Colonization Key to Candida auris Spread

Frontiers in Medicine Published July 31, 2026 DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize skin colonization as a key driver of Candida auris transmissibility and a target for future decolonization.

This systematic review synthesizes current knowledge regarding Candida auris infection, focusing on the role of skin colonization as a primary driver of transmission. The review highlights that C. auris is a multidrug-resistant pathogen characterized by high mortality rates and strong transmissibility in healthcare environments. Skin colonization is identified as a distinguishing feature from other Candida species and a key factor contributing to its ability to cause outbreaks.

The authors also explore the impact on skin microbiota, host immunoregulatory mechanisms, and various colonization mechanisms. While the review identifies these areas as critical for understanding the pathogen's behavior, it notes that the specific biological mechanisms underlying C. auris skin colonization remain poorly understood. Furthermore, the review indicates that relevant prevention and control strategies are currently underdeveloped.

From a clinical perspective, this synthesis aims to provide a theoretical basis for optimizing infection prevention and control measures. It highlights the need for more research into targeted decolonization intervention strategies. Because the review focuses on theoretical mechanisms rather than primary trial data, its application to specific clinical protocols is limited by the current lack of established evidence for standardized decolonization techniques.

A new systematic review highlights how Candida auris, a dangerous fungus, spreads in hospitals. The review explains that its ability to live on skin is a key reason it transmits so easily. This is different from other Candida species, which usually infect inside the body. The fungus is multidrug-resistant and causes outbreaks in healthcare settings, with a high death rate.

The review looked at studies on skin colonization, changes in skin microbes, and how the body's immune system responds. It also examined how the fungus attaches to skin and ways to remove it. However, the review did not report specific numbers, such as how many people were studied or how effective any decolonization method was. Instead, it aimed to summarize what is known and what is still unclear.

One major limitation is that the mechanisms behind skin colonization are still poorly understood. Prevention and control strategies are also underdeveloped. The review calls for more research to develop targeted ways to stop the fungus from spreading.

For patients and families, this means that hospitals are working to understand and control this tough infection. If you or a loved one are in a healthcare setting, good hygiene and infection control are important. But this review does not provide new treatment advice. Always talk to your doctor about any concerns.

What this means for you:
Candida auris spreads via skin colonization, but more research is needed for prevention.

Common questions

What is Candida auris?

Candida auris is a fungus that can cause serious infections. It is multidrug-resistant, meaning many antifungal drugs do not work against it. It spreads easily in healthcare settings and can cause outbreaks. The review notes it has a high mortality rate.

Why does Candida auris spread so easily?

The review says a key reason is that it can live on skin. This skin colonization is a distinguishing feature from other Candida species. It makes the fungus easy to transmit from person to person, especially in hospitals.

What can be done to prevent Candida auris infections?

The review says prevention and control strategies are still underdeveloped. It aims to provide a basis for better infection control and decolonization methods. For now, hospitals focus on hygiene and isolation. Talk to your doctor for specific advice.

More on Candida auris

Containment responses for Candida auris in hemodialysis facilities screened exposed patient contacts
Gastroenterology
Containment responses for Candida auris in hemodialysis facilities screened exposed patient contacts How do dialysis centers stop a dangerous fungus from spreading?
A report described containment responses at five hemodialysis facilities managing patients colonized with Candida auris, including screening…
When a dangerous fungus was found in five dialysis clinics, health officials screened other patients and took steps to stop the spread befor…
CDC Apr 3, 2026

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
Candida auris, as an emerging multidrug-resistant pathogen, has become a major threat to global public health due to its high mortality rate, strong transmissibility, and propensity to cause outbreaks in healthcare settings. Persistent skin colonization is a key factor contributing to the high transmissibility of C. auris and represents one of its important distinguishing features from other Candida species. However, the mechanisms underlying C. auris skin colonization remain poorly understood, and relevant prevention and control strategies are still underdeveloped. This article aims to systematically review the epidemiological characteristics of C. auris skin colonization, alterations in the skin microbiota, host immunoregulatory mechanisms, colonization mechanisms, and decolonization strategies, thereby providing a theoretical basis for further understanding the pathogenic mechanisms of C. auris, optimizing infection prevention and control measures, and developing targeted decolonization intervention strategies.
Read Next in Infectious Disease

Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures

Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk

JAMA · May 12
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.

Related in Infectious Disease

FDA Approves Veklury (remdesivir) for COVID-19 in Adults and Pediatric Patients
Infectious Disease FDA Approval
FDA Approves Veklury (remdesivir) for COVID-19 in Adults and Pediatric Patients FDA approves Veklury to treat COVID-19 in adults and children.
The FDA approved Veklury (remdesivir) for the treatment of COVID-19 in adults and pediatric patients (birth to less than 18 years weighing a…
The FDA approved Veklury (remdesivir) for treating COVID-19 in adults and children who are hospitalized or at high risk of severe disease. T…
FDA Aug 1, 2026
Hydrogen sulfide mediates bacterial antibiotic tolerance through iron chelation, efflux pump activation, and metabolic dormancy
Infectious Disease Sys. Review
Hydrogen sulfide mediates bacterial antibiotic tolerance through iron chelation, efflux pump activation, and metabolic dormancy Hydrogen Sulfide May Help Overcome Bacterial Antibiotic Tolerance
This systematic review synthesizes the role of hydrogen sulfide (H2S) in mediating multidrug tolerance in bacteria. The authors identify thr…
New research identifies how hydrogen sulfide helps bacteria resist antibiotics, offering a potential new way to target and eliminate persist…
Frontiers Jul 30, 2026
FDA Approves Dyna-hex 4 (chlorhexidine gluconate) for Healthcare Personnel Handwash
Infectious Disease FDA Approval
FDA Approves Dyna-hex 4 (chlorhexidine gluconate) for Healthcare Personnel Handwash FDA approves Dyna-hex 4 for handwashing and skin cleansing.
The FDA approved Dyna-hex 4 (chlorhexidine gluconate) for healthcare personnel handwash, skin wound cleansing, and general skin cleansing. T…
The FDA approved Dyna-hex 4 (chlorhexidine gluconate) for use as a handwash and skin cleanser in healthcare settings. It helps reduce bacter…
FDA Jul 29, 2026
FDA Approves Kaletra (lopinavir/ritonavir) for HIV-1 Infection in Adults and Children
Infectious Disease FDA Approval
FDA Approves Kaletra (lopinavir/ritonavir) for HIV-1 Infection in Adults and Children FDA approves new HIV drug Kaletra for adults and children.
FDA approved Kaletra (lopinavir/ritonavir) for treatment of HIV-1 infection in adults and pediatric patients 14 days and older, in combinati…
The FDA approved Kaletra (lopinavir/ritonavir) to treat HIV-1 infection in adults and children aged 14 days and older. It is used with other…
FDA Jul 29, 2026

From Other Specialties

Aorta recognized as independent organ; macrophages key in aortic disease diagnosis and treatment
Cardiology Sys. Review
Aorta recognized as independent organ; macrophages key in aortic disease diagnosis and treatment Aorta officially named an independent organ
This systematic review synthesizes current knowledge on macrophages in aortic physiology and pathophysiology. It highlights the 2024 EACTS a…
New guidelines call the aorta an independent organ, spotlighting immune cells that keep it healthy and drive disease.
Frontiers Aug 1, 2026
FDA Approves Cellcept (mycophenolate mofetil) for Organ Rejection Prophylaxis
Allergy & Immunology FDA Approval
FDA Approves Cellcept (mycophenolate mofetil) for Organ Rejection Prophylaxis FDA approves Cellcept to prevent organ rejection in transplant patients.
The FDA approved Cellcept (mycophenolate mofetil) for prophylaxis of organ rejection in adult and pediatric recipients 3 months and older of…
The FDA has approved Cellcept (mycophenolate mofetil) to help prevent organ rejection in patients who have received a kidney, heart, or live…
FDA Aug 1, 2026
FDA Approves Cellcept (mycophenolate mofetil) for Organ Rejection Prophylaxis
Allergy & Immunology FDA Approval
FDA Approves Cellcept (mycophenolate mofetil) for Organ Rejection Prophylaxis FDA approves Cellcept to prevent organ rejection in transplant patients.
The FDA approved Cellcept (mycophenolate mofetil) for prophylaxis of organ rejection in adult and pediatric patients 3 months and older rece…
The FDA has approved Cellcept (mycophenolate mofetil) to help prevent organ rejection in adults and children aged 3 months and older who hav…
FDA Aug 1, 2026
FDA Approves Myhibbin (mycophenolate mofetil) for Organ Rejection Prophylaxis
Allergy & Immunology FDA Approval
FDA Approves Myhibbin (mycophenolate mofetil) for Organ Rejection Prophylaxis FDA approves new liquid and capsule form of transplant rejection drug
The FDA approved Myhibbin (mycophenolate mofetil) for prophylaxis of organ rejection in adult and pediatric recipients 3 months and older of…
The FDA approved Myhibbin, a new form of mycophenolate mofetil, to prevent organ rejection in kidney, heart, and liver transplant patients a…
FDA Aug 1, 2026